Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Pegylated Interferon in Myelodysplastic/Myeloproliferative Syndrome with Ringsideroblasts and Thrombocytosis

Rudolf A. Benz, MD, Kathrin Zimmermann, Corinne C Widmer, MD MSc

Blood (2019) 134 (Supplement_1): 5433.

https://doi.org/10.1182/blood-2019-129077

Published: 2019

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

Journal Articles

Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012

Nicolas Bonadies, MD, Anita Feller, Alicia Rovo, MD, Axel Ruefer, MD, Sabine Blum, MD, Bernhard Gerber, MD, Georg Stuessi, MD, Rudolf A. Benz, MD, Nathan Cantoni, MD, Andreas Holbro, MD, Schmidt Adrian, MD, Thomas Lehmann, MD, Matthias Wilk, MD, Volker Arndt, MD MPH

Blood (2016) 128 (22): 5539.

https://doi.org/10.1182/blood.V128.22.5539.5539

Published: 2016

Journal Articles

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Beatrice Drexler, MD, Jakob Passweg, MD, Martin Bigler, Alexandre PA Theocharides, MD, Nathan Cantoni, MD, Peter Keller, MD, Georg Stuessi, MD, Axel Rüfer, MD, Rudolf A. Benz, MD, Geneviève Favre, MD, Alexandar Tzankov, MD, Pontus Lundberg, PhD, Andrea Fuhrer, PhD, Christine Biaggi, Markus G Manz, MD, Mario Bargetzi, MD, Simon Mendez-Ferrer, PhD, Radek C. Skoda, MD

Blood (2016) 128 (22): 3108.

https://doi.org/10.1182/blood.V128.22.3108.3108

Published: 2016

NARROW

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Pegylated Interferon in Myelodysplastic/Myeloproliferative Syndrome with Ringsideroblasts and Thrombocytosis

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Email alerts

ASH Publications

American Society of Hematology

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Pegylated Interferon in Myelodysplastic/Myeloproliferative Syndrome with Ringsideroblasts and Thrombocytosis

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only